<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443598</url>
  </required_header>
  <id_info>
    <org_study_id>GERMOP-002</org_study_id>
    <nct_id>NCT01443598</nct_id>
  </id_info>
  <brief_title>Pulmonary Hypertension in Interstitial Lung Disease</brief_title>
  <acronym>HYPID</acronym>
  <official_title>Observational Study of Patients With Pre Capillary Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HYPID study is an observational and prospective study of patients with interstitial lung
      disease and pre capillary hypertension diagnosed by right heart sided catheterization. The
      primary aim of the study is to identify prognostic factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre capillary pulmonary hypertension (PH) may be present in patients with diffuse
      interstitial lung disease.

      In this context, PH represents an important factor of morbidity and mortality for these
      patients.

      One of the purposes of HYPID is to determine predictive factors of mortality within this
      cohort of patients.

      In order to reach that aim,the study includes an evaluation based on exams conducted for the
      routine follow-up of patients. Each patient will be followed during 2 years at least.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Determine predictive factors of mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (1)</measure>
    <time_frame>2 years</time_frame>
    <description>Determine cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (2)</measure>
    <time_frame>2 years</time_frame>
    <description>Determine survival and time to worsening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (3)</measure>
    <time_frame>2 years</time_frame>
    <description>Analyse clinical, functional respiratory, hemodynamic features and changing characteristics of pulmonary hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (4)</measure>
    <time_frame>2 years</time_frame>
    <description>Document the efficacy of PH specific treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (5)</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the level of pulmonary arterial hypertension and compare the functional characteristics of patients with moderate or severe pulmonary hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (6)</measure>
    <time_frame>2 years</time_frame>
    <description>Analyse clinical, functional respiratory, hemodynamic features and changing characteristics of pulmonary hypertension</description>
  </secondary_outcome>
  <enrollment type="Actual">224</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Diffuse Interstitial Lung Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum and plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pre capillary pulmonary hypertension and interstitial lung disease at HRCT
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pre capillary pulmonary hypertension at right heart sided catheterization with: mPAP &gt;
             or = 25 mmHg,PCWP &lt; or = 15 mmHg

          -  interstitial lung disease with diffuse infiltrative opacities on chest CT scan

        Exclusion Criteria:

          -  pulmonary hypertension related to a thromboembolic disease

          -  respiratory disease other than diffuse interstitial lung disease

          -  any etiological factor of pulmonary arterial hypertension based on DANA POINT
             classification other than diffuse interstitial lung disease

          -  any progressive disease associated to a life expectancy less than 6 months other than
             pulmonary hypertension, diffuse interstitial lung disease and respiratory
             insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Cottin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon / University Lyon I</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Louis Pradel Hospital (BÃ¢timent A4)</name>
      <address>
        <city>Lyon</city>
        <state>Bron</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://maladies-pulmonaires-rares.fr/</url>
    <description>website National French Reference Center for rare lung diseases</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires</investigator_affiliation>
    <investigator_full_name>Vincent COTTIN</investigator_full_name>
    <investigator_title>Professor V. Cottin</investigator_title>
  </responsible_party>
  <keyword>Pulmonary arterial hypertension,</keyword>
  <keyword>Interstitial lung disease at HRCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

